Theravance Biopharma Inc. (NASDAQ:TBPH) shares traded down 3.1% during trading on Monday . The stock traded as low as $27.00 and last traded at $27.02, with a volume of 115,760 shares. The stock had previously closed at $27.89.

Several research analysts have commented on the company. Leerink Swann restated a “buy” rating on shares of Theravance Biopharma in a report on Saturday, June 4th. Bank of America Corp. downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Thursday, May 5th. Zacks Investment Research upgraded Theravance Biopharma from a “hold” rating to a “buy” rating and set a $26.00 price objective on the stock in a report on Tuesday, July 12th. Finally, Guggenheim started coverage on Theravance Biopharma in a research report on Monday, June 20th. They set a “buy” rating and a $30.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. Theravance Biopharma presently has an average rating of “Hold” and an average price target of $29.00.

The company’s market cap is $1.29 billion. The stock’s 50 day moving average is $24.67 and its 200 day moving average is $20.98.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by $0.01. Equities analysts forecast that Theravance Biopharma Inc. will post ($4.03) earnings per share for the current fiscal year.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.